Details for Patent: 8,945,621
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,945,621 protect, and when does it expire?
Patent 8,945,621 protects VIMOVO and is included in one NDA.
This patent has fourteen patent family members in fourteen countries.
Summary for Patent: 8,945,621
Title: | Method for treating a patient at risk for developing an NSAID-associated ulcer |
Abstract: | The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer. |
Inventor(s): | Ault; Brian (Wilmington, DE), Hwang; Clara (Wilmington, DE), Orlemans; Everardus (Chapel Hill, NC), Plachetka; John R (Chapel Hill, NC), Sostek; Mark (Wilmington, DE) |
Assignee: | Pozen Inc. (Chapel Hill, NC) Horizon Pharma USA, Inc. (Deerfield, IL) |
Application Number: | 12/822,612 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,945,621 |
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 8,945,621
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN | See Plans and Pricing | |||
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,945,621
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2010263304 | See Plans and Pricing | |||
Brazil | PI1012251 | See Plans and Pricing | |||
Canada | 2764963 | See Plans and Pricing | |||
China | 102481293 | See Plans and Pricing | |||
Eurasian Patent Organization | 201290026 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |